Fixed Duration Dosing of MONJUVI + rituximab and lenalidomide (R2)1

  • MONJUVI should be administered by a healthcare professional with immediate access to emergency equipment and appropriate medical support to manage IRRs
  • The recommended dose of MONJUVI is 12 mg/kg based on actual body weight administered as an intravenous infusion according to the dosing schedule in the table below
  • Administer MONJUVI in combination with rituximab 375 mg/m2 (Cycles 1 to 5) and lenalidomide 20 mg (Days 1-21 in Cycles 1 to 12)
  • Refer to the rituximab Prescribing Information and the lenalidomide Prescribing Information for the respective dosage recommendations
  • Administer MONJUVI as an intravenous infusion
    1. For the first infusion, use an infusion rate of 70 mL/h for the first 30 minutes; then, increase the rate so that the infusion is administered within 1.5 to 2.5 hours
    2. Administer all subsequent infusions within 1.5 to 2 hours

See Recommended Premedications for more information about MONJUVI premedications.

Fixed duration of dosing for MONJUVI (tafasitamab-cxix) plus rituximab and lenalidomide (R2). MONJUVI: 12 mg per kg IV for 12 cycles. Lenalidomide: 20 mg per day PO on days 1 - 21 of each 28 day cycle. Rituximab: 375 mg per m squared IV for 5 cycles.
Cycles (28 days each)1*
Cycle 1
MONJUVI (QW) 12 mg/kg IV on days 1, 8, 15, and 22
Lenalidomide 20 mg/day PO on days 1-21
Rituximab (QW) 375 mg/m2 IV on days 1, 8, 15, and 22
Cycles 2-3
MONJUVI (QW) 12 mg/kg IV on days 1, 8, 15, and 22
Lenalidomide 20 mg/day PO on days 1-21 of each cycle
Rituximab (QW) 375 mg/m2 IV on day 1 of each cycle
Cycles 4-5
MONJUVI (Q2W) 12 mg/kg IV on days 1 and 15
Lenalidomide 20 mg/day PO on days 1-21 of each cycle
Rituximab (Q4W) 375 mg/m2 IV on day 1 of each cycle
Cycles 6-12
MONJUVI (Q2W) 12 mg/kg IV on days 1 and 15
Lenalidomide 20 mg/day PO on days 1-21 of each cycle
Treatment completion
after 12 cycles

Refer to the rituximab Prescribing Information and the lenalidomide Prescribing information for the respective dosage recommendations, including lenalidomide dosage recommendations for patients with renal insufficiency.

MONJUVI is a 12-cycle fixed
duration treatment1

MONJUVI + R2 can be administered
in a local outpatient setting without
hospitalization required1

MONJUVI should be administered by a healthcare professional with immediate access to emergency equipment and appropriate medical support to manage infusion-related reactions.1 For details on dose modifications and management of adverse reactions for IRRs and myelosuppression, please refer to the full Prescribing Information.

*Recommended dose of MONJUVI is based on the patient’s actual body weight.1